Atlas Capital Advisors Inc. Has $6.03 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Atlas Capital Advisors Inc. boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5,620.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,466 shares of the biopharmaceutical company’s stock after buying an additional 8,318 shares during the quarter. Atlas Capital Advisors Inc.’s holdings in Regeneron Pharmaceuticals were worth $6,031,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $802,036,000. Amundi grew its holdings in Regeneron Pharmaceuticals by 45.8% during the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock valued at $1,138,074,000 after purchasing an additional 487,489 shares during the last quarter. Loomis Sayles & Co. L P raised its position in shares of Regeneron Pharmaceuticals by 33.4% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company’s stock valued at $1,122,168,000 after purchasing an additional 393,997 shares during the period. Proficio Capital Partners LLC lifted its stake in shares of Regeneron Pharmaceuticals by 92,865.3% in the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock worth $156,284,000 after buying an additional 219,162 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock worth $1,726,940,000 after buying an additional 155,369 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $625.60 on Thursday. The stock has a market capitalization of $68.39 billion, a P/E ratio of 16.34, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1 year low of $605.56 and a 1 year high of $1,211.20. The firm has a 50 day moving average of $680.43 and a 200-day moving average of $786.93.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the previous year, the company posted $11.86 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.56%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 2.30%.

Analyst Ratings Changes

REGN has been the topic of several recent analyst reports. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. BMO Capital Markets cut their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research report on Tuesday, February 4th. Bank of America reaffirmed an “underperform” rating and issued a $565.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Citigroup dropped their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Finally, Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $966.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.